A fter a long period of uncertainty and controversy, the role of T cell-mediated immunoregulation as one important peripheral tolerance mechanism controlling autoimmune responses has reemerged. Strong evidence came from the data demonstrating that depletion of selected T cell subsets using different experimental approaches led to established autoimmunity involving several target organs. Meaningful examples are those of the autoimmune syndrome elicited in susceptible mouse or rat strains rendered lymphopenic upon postnatal (day 3) thymectomy or following adult thymectomy and sublethal irradiation (1) (2) (3) . In both cases, disease is fully prevented by the transfer of the deficient immunoregulatory T cell subsets isolated from normal syngeneic donors based on their expression of particular cell receptors (CD25 ϩ T cells in the mouse (2), RT6 ϩ or CD62L ϩ cells in the rat (3, 4) ). Further evidence has been provided by experiments showing that sheep, rat, or mice that underwent pre-or postnatal ablation of organs such as the thyroid or the testis followed by their reimplantation develop an autoimmune thyroiditis or orchitis that is due to the absence of tissue-specific immunoregulatory T cells (5) (6) (7) (8) .
Initial data from our laboratory subsequently confirmed by other groups have shown that in the nonobese diabetic (NOD) 3 mouse model of spontaneous T cell-mediated autoimmune insulin-dependent diabetes, the onset of disease is under the control of CD4 ϩ immunoregulatory lymphocytes (ART, autoimmunity regulatory T cells (9) ), which appear in many respects similar to those downmodulating natural autoreactivity (9 -15) . Much of the phenomenology of this T cell-mediated immunoregulation has been frequently linked to the concept of immune deviation that is based on the existence of two main CD4 Th cell subsets Th1 and Th2 that counterregulate each other (16) . Thus, in the case of NOD diabetes, in which pathogenic CD4 T cells chiefly belong to the IFN-␥-producing Th1 subset (14, 17, 18) , the question is posed to determine whether immunoregulatory T cells that control the disease depend on Th2 cytokines for their differentiation, survival, or mode of action. Systemic administration of IL-4 or overexpression of IL-4 in islet ␤ cells prevents the occurrence of insulitis and diabetes (19, 20) . In addition, Th2 cells may indeed down-regulate the islet-specific pathogenic response in NOD mice notably after systemic administration of ␤ cell autoantigens (21) (22) (23) (24) .
In this study, we addressed this issue using a retrovirally based gene therapy approach in which diabetogenic or immunoregulatory T cells from NOD mice have been transduced with the murine IL-4 (mIL-4) gene and used in an adoptive transfer model we previously described. In this system, pathogenic T cells administered to immunoincompetent syngeneic adult recipients elicit disease, while the concomitant injection of immunoregulatory T cells efficiently protects from diabetes transfer. In this model, the Lselectin receptor (CD62L) was used as an instrumental marker to physically separate diabetogenic T cells, which lack CD62L, from immunoregulatory T cells that express it. After having shown that transduction with the mIL-4 gene of total spleen cells from diabetic mice inhibited their diabetogenic potential, we could evidence that the protection was mediated through a selective effect on immunoregulatory CD62L ϩ cells. These results might open new perspectives for gene therapy in humans using as targets peripheral T cells devoid of any intrinsic diabetogenic potential and without the need for a previous cell immortalization step.
Materials and Methods

Retroviral vectors and producer cell line
The retroviral vector pBABE-Neo containing the Mo-MLV long terminal repeats, the SV40 promoter, and the neomycin gene was kindly provided by Drs. Morgensten and Land (Imperial Cancer Research Fund, London, U.K.) (25, 26) . mIL-4 cDNA was cloned into BamHI site of the vector pBABE Neo. The ␤-galactosidase gene was used as a reporter gene. The ecotropic packaging line, GP ϩ E86, was transfected with pBABE Neo-IL-4 using calcium-phosphate precipitation. Transfected cells were selected and maintained in medium with 1 mg/ml G418 geneticin (Life Technologies, Gaithersburg, MD). Viral titers were at least 10 5 PFU/ml. Retroviral supernatants were stored at Ϫ80°C.
Mice and adoptive cell transfer
2), congenic Thy-1.1, and NOD-scid were bred in our animal facility under specific pathogen-free conditions. NOD females developed insulitis by 4 wk of age, and spontaneous diabetes appeared by 14 wk of age (95% incidence at 40 wk). Transgenic BDC2.5 NOD and NOD C␣ Ϫ/Ϫ mice were kindly provided by D. Mathis and C. Benoist (Institut de Génétique et de Biologie Moléculaire et Cellulaire, Strasbourg, France) and bred in our facility. These mice develop overt diabetes by 4 -6 wk of age. Colorimetric strips were used to monitor glycosuria (Glukotest; Boehringer Mannheim, Mannheim, Germany) and fasting glycemia (Haemoglukotest and Reflolux F; Boehringer Mannheim).
Adult 6-to 8-wk-old NOD-scid mice were used as recipients. Depending on the experiment, the animals were transferred either with a single cell population or, in the case of cotransfer experiments, with a mixture of two distinct cell populations. The precise cell numbers used varied depending on the experiments and are detailed in Results.
Abs and FACS analysis
Abs to CD3 (145 2C11), CD4 (GK1.5), CD8 (53.6.7), and TCR␣␤ (H57-597) were purified in our laboratory. For flow cytometry, Abs were fluoresceinated or biotinylated. MEL-14 (CD62L) was obtained from BD PharMingen (San Diego, CA). PE-labeled streptavidin used to detect the cell-bound biotinylated Abs was obtained from BD PharMingen. Briefly, cells were stained in PBS containing 5% heat-inactivated FCS and 0.01% sodium azide and incubated for 30 min with the appropriate concentration of biotin-labeled mAbs in 96-well round-bottom microplate on ice. After washing, the cells were incubated for another 30 min with FITC-labeled mAbs and PE-labeled streptavidin or PE-labeled mAbs. Control stainings were performed using isotype-matched biotinylated, FITC-or PE-labeled irrelevant Abs. Flow cytometry was performed on a FACScan flow cytometer (BD Biosciences, San Jose, CA). A minimum of 10 4 events was acquired on a gate including viable cells. For the acquisition and the analysis, the software used was CellQuest (BD Biosciences).
Cell preparations and infection with retroviruses
Splenocytes were recovered by gentle disruption from pools of 7-10 female mice (overtly diabetic Thy-1.2 or Thy-1.1 NOD, prediabetic Thy-1.2 NOD) and cultured in vitro (24-well culture plaques) in presence of Con A at 2.5 g/ml for 48 h at 37°C in a humidified atmosphere. The culture medium was RPMI 1640 (Life Technologies, Paisley, U.K.) supplemented with glutamax, 10% FCS (Life Technologies), 0.05 mM 2-ME, penicillin, and streptomycin. At the end of the culture, the cells were recovered, washed, and incubated at 37°C for 4 h at 5 ϫ 10 6 /ml in the viral supernatant previously warmed at 37°C and supplemented with DEAE dextran at 70 g/ml. Before transfer, the cells were washed twice in saline.
When needed, splenocytes were purified on the basis of the CD62L expression using MACS (Miltenyi Biotech, Bergisch-Gladbach, Germany), as previously described (13) . Briefly, splenocytes were incubated with the appropriate concentration of the biotinylated MEL-14 Ab, incubated with the streptavidin-coated paramagnetic beads, and passed through the magnetic column within the MACS device (Miltenyi Biotech) (13) . The purity of the recovered cells was analyzed by flow cytometry after staining with PE-labeled streptavidin. Purity of the sorted cells was in all cases greater than 97%, and recovery ranged from 50 to 70%.
Isolation of islet-infiltrating cells
Pancreata from NOD-scid recipients were recovered 12-15 days after transfer, and infiltrating cells were isolated by conventional collagenase digestion (collagenase-P, 5 mg/ml; Boehringer Mannheim) at 37°C for 5-8 min and hand picking under binocular lenses (27, 28) . Islets were then pressed through a 100-m metal sieve and filtered through a 40-m and a 20-m nylon screen to recover infiltrating cells. Cell viability was determined by trypan blue exclusion.
In vitro cultures and cytokine production
Cells were cultured in RPMI 1640 supplemented with glutamax, 10% FCS, 0.05 mM 2-ME, penicillin, and streptomycin. For cytokine production, lymphocytes were plated in triplicate (1 ϫ 10 5 /well; 200 l final volume), in 96-well round-bottom microplates (Nunc, Roskilde, Denmark) coated with 10 g/ml of purified TCR␣␤ Ab (H57-597). Supernatants were recovered at 48 h of culture at 37°in a humidified atmosphere containing 5% CO 2 , and stored at Ϫ80°C until tested. In control cultures, the TCR␣␤ Ab coating was omitted.
mIL-4 in the supernatants was measured by ELISA using 11B11 (provided by W. Paul, National Institutes of Health, Bethesda, MD) as a capture Ab and biotinylated BVD6 (provided by A. O'Garra, DNAX, Palo Alto, CA) as the secondary Ab. Mouse rIL-4 was from R&D Systems (Minneapolis, MN). The sensitivity of the IL-4 assay was 25 pg/ml.
Histopathology
Paraffin sections of Bouin-fixed pancreata were used. Serial 2-m sections were stained with hematoxylin and eosin to score mononuclear cell infiltration as follows: grade 0 ϭ normal islets; grade 1 ϭ focal or peripheral insulitis (lymphocytes surrounding the islet without destruction of endocrine cells); grade 2 ϭ invasive destructive insulitis. For each group and experimental condition examined, a minimum of 100 islets/mouse was scored.
Quantitative RT-PCR
RNA was extracted using TRIzol (Life Technologies), followed by isopropanol precipitation. Following reverse transcription, 50 -200 ng of reverse-transcription product was amplified using PCR for 30 cycles. The RT-PCR quantification was done using a multispecific internal standard (pMus) provided by D. Shire (Sanofi Recherche, Labège, France). The primers used were (Eurobio, Bioprobe, Les Ulis, France): IL-4, 5Ј-TCG GCA TTT TGA ACG AGG TC; IL-4, 3Ј-GAA AAG CCC GAA AGA GTC TC; ␤ 2 -microglobulin, 5Ј-TGA CCG GCT TGT ATG CTA TC; ␤ 2 -microglobulin, 3Ј-CAG TGT GAG CCA GGA TAT AG. RT-PCR products were separated by 1.2% agarose gel electrophoresis in TBE 1ϫ containing 0.2 g/ml of ethidium bromide and visualized under UV light.
Detection of the neo gene
Whole pancreas from NOD and NOD-scid mice, Con A-stimulated splenocytes from diabetic NOD, and islet-infiltrating cells from NOD-scid recipients injected with ␤-galactosidase-transduced cells were homogenized using a commercial lysis solution (Wizard genomic DNA purification; Promega, Madison, WI). The DNA was subsequently purified following manufacturer's recommendations. Genomic DNA (10 g) was digested with XbaI/EcoRI (Life Technologies), and the fragments were separated on a 0.8% agarose gel. DNA was transferred to Hybond (N ϩ ) membranes (Amersham, Arlington Heights, IL). The membranes were then hybridized with a 32 P-labeled bacterial neomycin phosphotransferase gene (neo r ) probe.
␤-galactosidase gene expression
The fluorescent lipophilic ␤-galactosidase substrate, fluorescein di-␤-Dgalactopyranoside, C 12 FDG (Imagene green; Molecular Probes, Leiden, The Netherlands), was used. When the substrate is cleaved by the enzyme, upon 2 h of incubation at 37°C, the green fluorescence of cells expressing ␤-galactosidase activity can be visualized by flow cytometry.
Statistical analysis
The occurrence of diabetes in the different experimental groups was plotted using the Kaplan-Meier method, i.e., nonparametric cumulative survival plot. The statistical comparison between the curves was performed using the logrank (Mantel-Cox) test, which provided the corresponding 2 values. In addition, when needed, results were analyzed using the Student's t test.
Results
Murine IL-4-based gene therapy prevents diabetes transfer
It has been well established that splenocytes from overtly diabetic NOD mice include pathogenic CD4 and CD8 T cells that adoptively transfer the disease into immunoincompetent recipients (12, 14, 29) . As we have previously shown, the i.v. injection of 2-10 ϫ 10 6 total splenocytes into NOD-scid recipients triggers overt diabetes within 4 -6 wk (10 -13).
Using this experimental system, we investigated the effect of retrovirally mediated mIL-4 gene therapy on disease transfer.
To ensure ideal conditions for the integration of the retroviral gene, which mostly occurs upon cell proliferation, all splenocyte populations used were stimulated with the polyclonal activator Con A. In a preliminary set of experiments, we confirmed that the diabetogenic capacity of Con A-stimulated spleen cells from overtly diabetic NOD was identical with that observed with unstimulated populations (data not shown, see Fig. 1 legend) . Mice recipients of splenocytes infected with a ␤-galactosidase retrovirus were used as controls and exhibited an incidence and kinetics of disease transfer superimposable to that observed in animals injected with uninfected and unstimulated or Con A-stimulated splenocytes from diabetic NOD mice (Fig. 1) . The ␤-galactosidase gene served both as a control for the IL-4 gene and as a reporter gene to trace the homing to islets of transduced cells by means of cell labeling using a fluorescent lipophilic substrate (see below).
As shown on Fig. 1 , diabetes transfer was very significantly and reproducibly affected when mature cells, recovered from the spleen of overtly diabetic NOD mice, were transduced with mIL-4. Thus, the data from three independent experiments obtained at 8 -12 wk after transfer showed that overt disease appeared in only 0 -20% of mice injected with mIL-4-transduced T cells as compared with 80 -100% of mice in the control groups ( Fig. 1) .
At 24 h and 48 h from the infection, we quantified by competitive RT-PCR the expression of specific mIL-4 mRNA within cells infected with the mIL-4 or the ␤-galactosidase retrovirus. As shown on Fig. 2 , at 24 h of in vitro culture, a higher amount of specific mIL-4 mRNA was observed in mIL-4-transduced cells as compared with uninfected control. Moreover, at 48 h of culture, only in mIL-4-transduced cells was the expression of mIL-4 mRNA detected (Fig. 2) . These results suggest the possibility of achieving a specific and relatively high retroviral gene expression.
Recipients protected from disease transfer by mIL-4-based gene therapy exhibit peripheral/noninvasive insulitis
Upon transfer of diabetogenic cells, NOD-scid recipients showed a progressive infiltration of the target tissue, namely the islets of Langerhans (i.e., insulitis). Histological studies were performed in mice receiving mIL-4-transduced cells as well as in controls. Pancreata were recovered at 4 and 9 wk following transfer and processed as already described according to conventional procedures (13) . Infiltration was present in all experimental groups (Fig. 3) . However, the topography of the infiltration significantly varied between the experimental groups. As shown on Fig. 3 , in control mice that received ␤-galactosidase-transduced T cells and that developed a high disease incidence, the majority of islets (ϳ90%) showed a pattern of invasive/destructive insulitis. In clear contrast, in mice that were protected from disease through the injection of mIL-4-transduced cells, the vast majority of the islets were either intact (25%) or presented with (60%) an infiltration that remained confined to the periphery of the islets (noninvasive peri-insulitis). This pattern was stable over time because identical results were scored at 9 wk after transfer.
Islet-infiltrating T cells express the retroviral encoded proteins, mIL-4 and ␤-galactosidase
Different methods were used in parallel to assess the presence of the retroviral gene and of the transduced proteins within islet-infiltrating cells. Concerning the retroviral gene, Southern blots were performed to evidence the neo r gene. In fact, the retroviral vectors were engineered to include, in association with the mIL-4 or ␤-galactosidase genes, the bacterial neomycin phosphotransferase gene (neo r ). As shown on Fig. 4 , the digested fragment of 1200 bp containing the neo r gene, indicating the presence of the retroviral vector, was present in DNA samples prepared using islet-infiltrating cells from NOD-scid recipients of ␤-galactosidase-transduced cells.
Importantly, the expression of the transduced proteins, mIL-4 or ␤-galactosidase, was also evidenced within islet-infiltrating lymphocytes from adoptively transferred mice. In recipients of mIL-4-transduced cells, infiltrating lymphocytes, recovered at 12 days from transfer, produced significant levels of mIL-4, upon polyclonal stimulation using an immobilized TCR␣␤ Ab (as compared with control recipients of ␤-galactosidase-transduced cells), as assessed by specific ELISA (Fig. 5A) . We also investigated the expression of ␤-galactosidase activity in pancreatic infiltrating cells recovered at 15 days from transfer in recipients of diabetogenic ␤-galactosidase retrovirus-infected cells. To this aim, we took advantage of the C 12 FDG lipophilic substrate that is fluorescent upon cleavage by ␤-galactosidase. The green fluorescence of the cleaved substrate could be easily measured by flow cytometry, and the results showed that ϳ60% of TCR␣␤ ϩ islet-infiltrating cells expressed a significant ␤-galactosidase activity (Fig. 5B) .
Cells expressing the retroviral encoded mIL-4 were also found in spleen cells from recipients of mIL-4. As shown on Fig. 5C , mIL-4 levels were significantly higher in supernatants from TCR␣␤ Ab-stimulated cultures using splenocytes from recipients of mIL-4-transduced cells as compared with control recipients of ␤-galactosidase-transduced cells.
We took advantage of mixing experiments in the adoptive transfer system, using mixtures of cells from Thy-1.1 and Thy-1.2 congenic NOD mice, to further prove that the mIL-4 production observed was essentially derived from the mIL-4-transduced splenocytes. Thus, adoptive transfer was performed using mixtures of uninfected diabetogenic Thy-1.1 cells (from the spleen of diabetic Thy-1.1 NOD mice) and purified mIL-4-transduced CD62L ϩ splenocytes from prediabetic Thy-1.2 congenic NODs. Recipients' spleen cells were recovered at 21 days from transfer, and the Thy-1.1 and Thy-1.2 subsets were purified by means of magnetic beads sorting. These purified subsets were then tested in vitro for their mIL-4-producing ability. As shown on Fig. 5D , mIL-4 production almost exclusively originated from the infected Thy-1.2 subset.
Some of these supernatants using splenocytes recovered from different experimental groups were also tested for their levels of IFN-␥ by specific ELISA. A similar IFN-␥ production (ranging from 42 to 68 ng/ml) was detected in bulk splenocyte cultures from mIL-4-transduced or nontransduced CD62L ϩ cells and from nontransduced CD62L
Ϫ cells. Thus, the deduced IFN-␥/IL-4 ratio was significantly decreased in supernatants from mIL-4-transduced CD62L ϩ splenocytes when compared with those from nontransduced cells (data not shown).
mIL-4 gene therapy has no effect on diabetogenic cells, but selectively potentiates the functional capacity of immunoregulatory lymphocytes
As we previously discussed, T cells present in the spleen of prediabetic and diabetic mice are functionally distinct. These include diabetogenic CD4 ϩ and CD8 ϩ T cells that transfer acute diabetes into immunoincompetent syngeneic recipients and a subset of immunoregulatory CD4 ϩ T lymphocytes mediating "active tolerance" that control the pathogenic potential of diabetogenic effectors (11) (12) (13) (14) . These immunoregulatory T cells are assessed through their capacity to inhibit adoptive transfer of disease by diabetogenic lymphocytes.
We therefore explored whether there was or not a selective T cell target (i.e., diabetogenic cells and/or immunoregulatory cells) responsible for the protective effect observed upon mIL-4 gene therapy.
In these experiments, we took advantage of the results we already discussed demonstrating that the L-selectin receptor (CD62L) is a unique marker to physically purify diabetogenic lymphocytes and separate them from immunoregulatory T cells (10) . Thus, in overtly diabetic NOD mice, pathogenic splenocytes that transfer diabetes are exclusively included within the CD62L Ϫ T cell population. Conversely, CD62L
ϩ T cells are totally devoided of any diabetogenic potential (10) , and cotranfer experiments confirmed that even in overtly diabetic mice they do include significant proportions of immunoregulatory T cells (10, 11) .
Selective mIL-4 gene therapy of diabetogenic effector cells
Retroviral mIL-4 infection of purified polyclonal CD62L
؊ cell splenocytes. Purification of spleen T cell subsets was performed as already described by means of magnetic beads cell sorting using the CD62L-specific Ab MEL-14 (10, 11, 13). We first examined whether mIL-4 transduction of purified CD62L
Ϫ cells could modulate their capacity to transfer diabetes. Results clearly showed FIGURE 4. Detection of retroviral DNA from isolated pancreas-infiltrating cells. Southern blots using a probe specific for the bacterial neomycin phosphotransferase (neo r ) gene were performed on various DNA samples including: control Con A-stimulated but uninfected splenocytes from diabetic NOD mice, control pancreatic tissue from NOD and NODscid mice, and islet-infiltrating cells from recipients transferred with ␤-galactosidase transduced cells. ( Fig. 6A ) that, independently from the dose of cells (0.4 ϫ 10 6 , 1 ϫ 10 6 , 5 ϫ 10 6 ), the diabetogenic capacity of CD62L Ϫ T cells was not influenced upon retroviral mIL-4 gene transfer ( p ϭ 0.241 for the two cell number conditions detailed on Fig. 6A ). Recipients transferred with 5 ϫ 10 6 purified diabetogenic CD62L Ϫ cells showed 100% diabetes at 3 wk from transfer. Retroviral mIL-4 infection of transgenic clonotypic diabetogenic splenocytes. We next determined whether cells expressing a monoclonal diabetogenic TCR could be modulated upon mIL-4 transduction in their ability to transfer diabetes. To this aim, we used splenocytes from BDC 2.5/C␣ Ϫ/Ϫ transgenic mice expressing a rearranged ␣␤ TCR from a CD4 ϩ diabetogenic T cell clone (17, 30) . In BDC 2.5/C␣ Ϫ/Ϫ transgenic mice, the proportion of CD4 ϩ T cells expressing CD62L is 50 to 70% lower than that observed in wild-type NOD. In fact, the transgenic cells preferentially express an activated/memory phenotype.
As shown on Fig. 6B , the incidence and the kinetics of diabetes transfer were identical with infected or uninfected BDC 2.5/C␣ Ϫ/Ϫ splenocytes.
Selective mIL-4 gene therapy of immunoregulatory cells
Adoptive cotransfers were performed according to a modification of the method initially described by Boitard et al. (12) . NOD-scid recipients (4 -5 wk of age) were injected i.v. with mixtures of two distinct populations, namely uninfected splenocytes from diabetic NOD mice (diabetogenic cells) and mIL-4-transduced or nontransduced purified CD62L ϩ T cells from the spleen of prediabetic NOD mice (Fig. 6C) . In these experiments, mice injected with uninfected diabetogenic cells alone were used as positive controls.
The results showed, as already described (11, 13) , that uninfected CD62L
ϩ cells inhibit diabetes transfer in a dose-dependent fashion. Moreover, at all dosages of CD62L ϩ cells used, the retroviral mIL-4 infection reproducibly improved their protective ability (Fig. 6C ). The differences observed in diabetes transfer between recipients of nontransduced vs mIL-4-transduced CD62L 
Discussion
The i.v. injection of splenocytes from diabetic NOD mice into NOD-scid recipients triggers diabetes in ϳ4 -6 wk. In a first step, we have used these unseparated splenocytes to investigate the capacity of retroviral mIL-4 gene therapy to modulate diabetes transfer. Transduction experiments were conducted in parallel with the IL-4 or the control ␤-galactosidase gene. After the infection and before cell transfer, a significant amount of specific IL-4 mRNA was detected in cells infected with the mIL-4 retrovirus, thus confirming the effective transcription and overexpression of the retrovirally transduced gene.
Diabetes transfer was significantly and reproducibly reduced when spleen cells from diabetic mice were IL-4 transduced. At variance, recipients of ␤-galactosidase-transduced cells exhibited an incidence and kinetics of disease transfer superimposable to that observed in animals injected with uninfected splenocytes. These results argue against possible nonspecific bystander immune interference mediated either by the viral vector or the local expression of a transgene.
Progressive insulitis, i.e., infiltration of the pancreatic islets was detected in recipients of both ␤-galactosidase-and IL-4-transduced cells. However, the topography of the infiltration varied significantly between the experimental groups. Mice receiving ␤-galactosidase-transduced T cells, which developed a high incidence of disease, had invasive/destructive insulitis. In clear contrast, in mice that were protected from disease by the injection of IL-4-transduced cells, a vast majority of the islets were either intact or had an infiltrate that remained confined to the periphery of the islets (noninvasive peri-insulitis).
Several methods allowed us to assess the expression of the retroviral genome and of the transduced proteins within these isletinfiltrating cells. In Southern blots performed on DNA preparations using pancreatic infiltrating cells from recipients of transduced cells, the genomic bacterial neomycin phosphotransferase gene band (neo r ), included within the retroviral vectors, was detected. Importantly, in recipients of mIL-4-transduced cells, pancreatic infiltrating lymphocytes, recovered 12 days after transfer, produced significant levels of IL-4. The expression of ␤-galactosidase activity among pancreatic infiltrating cells, in recipients of ␤-galactosidase-transduced cells, was also investigated using the C 12 FDG lipophilic substrate, which becomes fluorescent upon cleavage by the enzyme. Results showed that ϳ60% of TCR␣␤ ϩ islet-infiltrating cells expressed significant ␤-galactosidase activity.
As a whole, these ex vivo data confirm the reality of the IL-4 gene transduction and provide direct support, not available from previous studies, that the transduced cells home to the target organ, namely the islets, and produce locally a significant amount of the retrovirally transduced cytokine.
Our previous data have indicated that, even at an advanced stage of disease, peripheral T cells from NOD mice include both diabetogenic T cells and nondiabetogenic immunoregulatory CD4 ϩ T cells (11) (12) (13) . We wondered whether the gene therapy effect was concomitantly exerted on these two subsets or selectively in one of them. The present results clearly showed that selective transduction of purified effector cells did not inhibit their diabetogenic potential when these cells were administered alone to immunoincompetent hosts. We first took advantage of our demonstration, discussed above, that L-selectin (CD62L) is absent from diabetogenic T cells (10) to examine whether IL-4 transduction of purified diabetogenic CD62L Ϫ cells could modulate their capacity to transfer diabetes. This discrimination afforded by CD62L appeared particularly useful in the context of these studies, in which it was necessary to separate regulatory from effector cells. CD25 has recently been described as another important marker of ART cells in NOD mice (15) , but it appeared less attractive in this study because there is not yet definitive proof that CD25 Ϫ cells only include diabetogenic effectors as CD62L Ϫ cells do. Results clearly showed that the diabetogenic capacity of CD62L Ϫ T cells was not modified upon retroviral IL-4 transduction. Importantly, this was true independently from the number of cells transferred, which was as high as 5 ϫ 10 6 of IL-4-transduced or nontransduced CD62L Ϫ T cells per recipient. These results, obtained with polyclonal diabetogenic cells, were then extended to transgenic (monoclonal) diabetogenic splenocytes from BDC2.5 C␣ Ϫ/Ϫ transgenic mice. These mice express a rearranged TCR␣␤ from a CD4 ϩ diabetogenic T cell clone (30). The incidence and kinetics of diabetes transfer were identical with infected or uninfected BDC2.5 C␣ Ϫ/Ϫ splenocytes. This is well in keeping with the data showing that, at variance with conventional NOD, ␤ cell overexpression of IL-4 does not protect BDC2.5 TCR transgenic NOD mice from diabetes (31) . It was then suggested by the authors that T cell diversity and expansion of what they defined "nonpathogenic" specificities were required for the counterregulating effect of diabetes induced by IL-4 (31). This conclusion was in support of the hypothesis that locally delivered IL-4 did not act directly on diabetogenic effectors, but rather indirectly through a distinct target cell type (31) . It was thus not surprising to observe that selective transduction of the IL-4 gene in CD62L ϩ regulatory cells strongly potentiated the functional capacity of these cells. Cotransfers were performed as previously described (12) . NOD-scid recipients were injected with mixtures of two distinct populations, namely uninfected diabetogenic splenocytes from diabetic NOD mice, and IL-4-transduced or nontransduced purified CD62L ϩ T cells from the spleen of prediabetic NOD mice. In these experiments, mice injected with uninfected diabetogenic cells alone were used as positive controls. As previously reported, uninfected CD62L ϩ cells inhibited diabetes transfer in a dose-dependent fashion. Using suboptimal doses of CD62L ϩ immunoregulatory cells, providing only partial protection, we could evidence that retroviral IL-4 infection reproducibly augmented their protective ability.
Two distinct nonmutually exclusive hypotheses may be proposed to explain these results. The first is that of a selective effect of the mIL-4 gene therapy on the subset of CD4 ϩ CD62L ϩ T cells (ART immunoregulatory lymphocytes) that control spontaneous diabetes onset. Alternatively, phenotypically naive CD62L ϩ lymphocytes may differentiate, upon mIL-4 transduction, into classical Th2-type cells involved in mediating the protection. In favor of this conclusion is our present data showing that the IFN-␥/IL-4 ratio is decreased in supernatants from splenocytes including mIL-4-transduced CD62L ϩ cells that mediate the protection. Another important and still pending question is whether IL-4 gene therapy will exert its effect in cis, the transduced cell being the effector of the protection, or in trans, through the recruitment of nontransduced effectors.
An interesting aspect of the described mIL-4 gene therapy is its effectiveness on fully differentiated T cells recovered from NOD mice at a late stage of the disease. This is at variance with most previous data showing that IL-4-based therapies (systemic delivery of the cytokine or transgenic ␤ cell overexpression) could prevent disease in NOD mice only when applied at a very early stage (19, 20) . Conversely, our results are in keeping with the data showing that Lentivirus-mediated transduction of islet grafts with IL-4 protected them from autoimmune destruction once implanted into diabetes-prone NOD mice (32) .
At the therapeutic level, the interest of such a late therapeutic effect is obvious because immunotherapy of human diabetes will involve in the first place subjects with relatively advanced autoimmune disease history. Cytokine-based gene therapy of autoimmune diabetes has to date essentially involved either the transduction of somatic cells, affording the systemic delivery of the cytokine (33) (34) (35) , or of the disease target, namely islet cells (32, 36) . More limited data are also available in diabetes and other autoimmune diseases using transduced T cell clones or T cell hybridomas (37, 38) . The strategy we used in this study circumvents first the need for the transduction of ␤ cell that is hardly feasible in humans, and second the usage of immortalized or long-term culture T cells that may also be delicate to achieve in humans.
